Abstract 154P
Background
The variants of urothelial carcinoma such as micropapillary (MP), plasmacytoid (PC), and lipid cell (LC) carry a very poor prognosis. High progression speed and resistance to chemotherapy are considered to be part of the reasons for poor prognosis. Accordingly, early diagnosis and early treatment are important to improve prognosis. In this study, we elucidated the cytological diagnostic criteria of these variants, and also investigated whether preoperative urine cytology could diagnose these variants and the possible association between cytological predictability and pathological features.
Methods
Between April 2015 and March 2020, 45 patients were histologically diagnosed as MP, PC, and LP by TURBT in our institution. The experienced cytologists (YW) in our hospital re-evaluated the preoperative urine cytology in these cases to determine whether or not the prediction of the variant histology is possible. The following findings were used as criteria, small papillary cell clumps with strong binding in MP, circular atypical cells similar to plasma cells in PC, and atypical cells similar to lipoblasts with empty cells in LC. Additionally, we analyzed whether histopathological findings such as muscle invasion, tumor size, tumor necrosis, lymphovascular invasion (LVI), CIS, affect the prediction of the variants.
Results
Of 45 cases, MP, PC and LC were 18 (40%), 13 (29%) and 14 (31%) patients, respectively. 3 cases of MP (17%), 5 of PC (38%) and 2 of LC (14%) could be predicted by re-evaluating preoperative urine cytology. In addition, positive preoperative urine cytology (class 4 or higher) was found in 14 cases in MP (78%), 8 cases in PC (62%), and 11 cases in LC (79%), with estimated probabilities of 21%, 62%, and 18%, respectively. Pathological features were not different between the predictable and unpredictable cases: muscle invasion, 90% vs 74% (P = 0.26); median tumor size, 31 mm vs 38 mm (P = 0.37); tumor necrosis, 20% vs 28% (P = 0.64); LVI, 60% vs 45% (P = 0.42); CIS, 40% vs 34% (P = 0.74), respectively.
Conclusions
Although in some cases, atypical cells suggesting UC variants appeared in the urine cytology, this study suggested that the preoperative cytological diagnosis of bladder cancer variants seems to be difficult.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract